Evidence map›Paper›PMID 40394658›Full record

ArticleJournal of nanobiotechnology2025

Co-encapsulation of norcantharidin prodrugs and lomitapide in nanoparticles to regulate CCL4 expression by inhibiting Wnt/β-catenin pathway for improved anti-tumor immunotherapy.

Feng Zhao, Liming Gong, Ping Wang, Dong Chen, Shijie Cao, Feifei Yang, Manqing Tang, Yuanyuan Meng, Yuming Wang, Lin Miao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Feng Zhao *College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Liming Gong *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Ping Wang *College of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Dong ChenSuzhou Kintor Pharmaceuticals, Inc., Suzhou, 215127, China.
Shijie CaoState Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Feifei YangKey Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicines, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100193, PR China.
Manqing TangCollege of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Yuanyuan MengCollege of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Yuming WangCollege of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
Lin MiaoState Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. mmmlin@tjutcm.edu.cn.
Yunfei LiCollege of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. liyunfei@tjutcm.edu.cn.
Wei HuangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China. huangwei@imm.ac.cn.

Funding

CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-026Jilin Province Science and Technology Development Plan Item YDZJ202501ZYTS818Open Projects Fund of Shandong Key Laboratory of Carbohydrate Chemistry and Glycobiology, Shandong University 2023CCG13
6 · The paper itself

Abstract

In the absence of tumor antigen specificity, direct chemokine administration carries the risk of significant "on-target, off-tumor" toxicities, highlighting the need for small-molecule approaches with reduced immunogenicity. This study investigates the synergistic potential of norcantharidin (NCTD) and lomitapide (lomi) in selectively restoring CCL4 expression by deactivating the tumor intrinsic β-catenin pathway. Due to its similar lipophilicity to lomi and potential to suppress β-catenin, NCTD prodrug (C12) was selected to be co-encapsulated with lomi in a nanoparticle-mediated co-delivery system (NP"C12 + lomi"). The NP"C12 + lomi" formulation exhibited a high encapsulation rate, uniform particle size, and suitability for therapeutic use. It effectively inhibited the proliferation of 4T1 cells and restored CCL4 expression. In both primary breast tumor and surgically resected tumor mouse models, NP"C12 + lomi" significantly increased the proportion of CD8

Indexed as

Bridged Bicyclo Compounds, HeterocyclicImmunotherapyNanoparticlesProdrugsWnt Signaling PathwayAnimalsAntineoplastic Agentsbeta CateninCell Line, TumorCell ProliferationFemaleHumansMiceMice, Inbred BALB CAntineoplastic Agentsbeta CateninBridged Bicyclo Compounds, HeterocyclicnorcantharidinProdrugsChemokine immunotherapyMetastasis mitigationNanoparticle colocalizationSmall molecule strategyβ-catenin inhibition

Identifiers

PMID40394658
PMCPMC12093795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.